NR1H4 and breast carcinoma: Thus, our results, highlighting the ability of activated FXR to counteract leptin signaling responsible for mammary carcinogenesis within the tumor microenvironment, support the possibility that FXR ligands could represent a promising pharmacological tools to be exploited in the novel strategies for breast cancer treatment.